Anticipation Of Action

Where are we? Holds are gone. So now what? We aren't still fighting, or are we? Things are better now, right? Not according to the share price, but, yes, things are much better now regardless of share price.

What do we know? Well, we know where we are headed and that is towards something great.

But where are we exactly in the process of getting there? Right now, it seems as if it is kind of complicated, that we just can't see what the next steps are exactly; we can see them but only blurred out, but not precisely, nor how far they are away or how close, nor are their edges defined and clear cut. However, that day ahead does come to pass when everything turns abruptly 180 degrees around.

So, given all that which we already know, I make an educated guess based on that. I do suspect that the next webcast happens on April 9, 2024, which makes it a quarterly call. I prefer to go on company statements and not my own hyperbole. I prefer to base conjecture on statements made by company leaders.

Given that the holds are forever gone, you would hope that the disclosures made on the call would be big. We've waited for so long and finally got to that which we've been hoping for, so you would tend to think that they would tell us exactly what we want to hear. Like a partnership or an infusion of money from some grant or VC fund based on the lift of the hold. This long period of languishing gave so many the opportunity to load the boat and many did just that declaring a large showing of faith, hope and expectation in reaching this goal, as leronlimab has been proven safe by the Administration. Why then has not Peace also followed in turn?

Dr. Lalezari quickly got the hold lifted and now, 3- 4 months following his hire, the time comes for the first conference call webcast where many shareholders hope to hear big news in the camp. After all, CytoDyn proved to the FDA that leronlimab was clinically and scientifically safe. CytoDyn produced all the documentation, all the studies, all the articles, and all the properly formatted data. CytoDyn produced their protocols and standard procedural practices demanded by the FDA; they produced the results of prior clinical trials; they cleaned up their website and revised the methods they used to use to provide information. Lastly, they negotiated upon a protocol for the coming trial that the FDA would be comfortable with, for the indication of Attenuation of Inflammation and Immune Activation. All that led to proof of Safety, but wouldn't it also lead to Peace at CytoDyn?

After all was said and done, the FDA did lift the holds on leronlimab and the Administration did so because leronlimab was worthy, because it was proven safe by their own standards, and because they could not find a reason to disqualify it. Certainly, there was no luck or happenstance involved in its release from captivity. Simply said, leronlimab earned its freedom and it deserved to be unshackled because CytoDyn worked its ass off in this pursuit.

Many believed that CytoDyn could never pull this off. They believed that it was too big a hurdle for CytoDyn to overcome. But just as the sly youngling David was considered no match for the giant Goliath, so did CytoDyn overcome the government-imposed holds. Yes, it is understood that it didn't happen overnight, and neither shall it happen overnight in consideration of the coming next step. But just as it was done for the holds, so shall the coming next step be also accomplished and fulfilled. Now, though, with no dead weight tying CytoDyn to the walls of a prison cell, CytoDyn is free to act as a BioPharmaceutical should, in the ways and by the means necessary that develop and advance their molecule.

Because of what CytoDyn has accomplished, because they were successful in getting the holds lifted, I see that they are capable of achieving anything they set their eyes upon. I see that all who may come against them, shall not prevail, but rather, CytoDyn's strength shall gradually and progressively grow day by day, month by month, year by year. Shareholders are stalwart and the leaders of CytoDyn are aware of their shareholders confidence. The leaders know to do the right thing at the right time, and this becomes CytoDyn's protection, the unification of purpose between Shareholders and company leadership. CytoDyn's shareholders become more and more convinced of the competence of leadership because they actually accomplish and perform what they have set out to do, what they said they want to accomplish. So, this then develops that confidence in shareholders, and therefore, they become even more increasingly tenacious. This all translates into a complete win for CytoDyn. This is how CytoDyn proceeds now. This starts off right now, albeit very slowly, but slowly gains momentum, yet rest assured, it remains solidly planted on its feet, stable and upright.

Shareholders are on the CytoDyn train, and the tracks are laid or at least defined. Of importance in the course of the next few months are the Immune Activation and Inflammation Clinical Trial and exactly how of course, it shall be funded; the settlement of the Amarex arbitration, the monetary quantity of that settlement, and the quality of and how quickly those monies can be paid; the initiation of the GlioBlastoma Multiforme and Alzheimer's murine clinical studies and the publication of the (4) peer reviewed articles.

So, what can we understand? We can know that with the shackles removed, that CytoDyn is at work obtaining answers to the above questions. We can expect at least explanations to some of these questions in the coming quarterly webcast conference call. While CytoDyn is at work towards the development and advancement of leronlimab realize also that CytoDyn is only at the beginning stages of developing and assembling the trial of the century because this trial, albeit a Phase II clinical trial, becomes the defining trial for CytoDyn, the go or no go trial for CytoDyn as it either makes or breaks this drug, as it either determines that it is capable of Attenuating and Mitigating Immune Activation and Inflammation or determines that it is not capable. We know that it is anecdotally capable of these things, but "Can it be scientifically proven?" is the question. So CytoDyn has to get this right and they have to do it in a way which does not fail. Like Lalezari has done so far since his hire, he does again, which means he does not fail. So, in the end, when the trial finishes, Lalezari has proof positive that leronlimab is the only Attenuator and Mitigator of Immune Activation and Inflammation that the world has, and he waves that flag high.

Somehow, I believe someone, or something is to be introduced that allows CytoDyn to progress down the tracks unimpeded. It may take some time for CytoDyn to arrive to its destination and some will power of course, but as the train begins to apply power to those rails, it builds upon its own momentum and increases speed as it progresses towards its goal. Could that someone be Mitch Cohen who has not yet made his own introduction just yet? Possibly. Let's see if he is introduced during the call. We should be better able to judge him once we hear from him. It would be nice to hear from Scott Hansen PhD once again on the progress they have made on the long acting leronlimab molecule. From the opposite perspective, maybe, the shorts puppet master calls off the shorts and allows the share price to fluctuate naturally. Possibly, the market makers leave well enough alone for the next few years to allow CytoDyn to grow as it otherwise could without their suppressive influence. Will this happen? Hopefully.

1. Holds are gone because leronlimab is proven safe.
2. Turning point, but it is cloaked undercover as there is no money to proceed, so the need to produce peer reviewed journal articles to increase share price, the need to settle and collect from Amarex and the need to complete the murine studies.
3. Mitch Cohen hired and could create an Action that propels this forward. Short traders could be called off. Scott Hansen PhD may have something to say on LALL.
4. Lalezari's plans that develop and advance leronlimab are gradually and progressively performed, undertaken and accomplished, little by little, day by day, month by month and year by year, unimpeded, growing in momentum, purposeful and deterministic, proving leronlimab as the only Attenuator and Mitigator of Immune Activation and Inflammation on this green Earth, such that the whole world knows this fact. How much is this valued at? What does this cause?

​

The logistics of how this gets done is not the point of this post. The point is that it does get done, by hell or by high water, it gets done. By whose order? Could be Lalezari's, could be Cohen's, could be Arman's, don't know. Some Action could be that more might need to be hired, Lalezari's communications with CRO, Tyler Blok's and Sidley Austin's negotiations with Amarex, ... and on and on, but it gets done. It shall be done despite the adversity. Despite the lack of funds, finding the CRO, waiting for Amarex's return argument and the sheer wait for the trial to begin, to execute with concluding results could prove to be difficult, but because of first and foremost, those who runs this, and what their track records are, we can be assured, that this pans out in greater ways than how even they envision it unfolding. The indication market of Inflammation and Immune Activation is utterly massive, and they know this but are toning down their remarks as they remain under FDA scrutiny.

​